Catalyst
Slingshot members are tracking this event:
Top-line results from Esperion's (ESPR) pivotal Phase 3 Study 3 (1002-046) of bempedoic acid in ASCVD patients on less than approved daily starting doses of statins (high CV risk patients considered statin intolerant) expected May 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ESPR | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 03, 2018
Occurred Source:
http://investor.esperion.com/releasedetail.cfm?ReleaseID=1065889
Related Projects
- Evaluating the market for LDL-C lowering medications like Bempadoic Acid from Esperion Therapeutics ESPR Executed On: Nov 06, 2018 at 01:00 PM EST
Related Keywords
Phase 3 Study, Bempedoic Acid, Ascvd, Statins, High Cv Risk
